Research programme: urokinase inhibitors - Wilex/4SC

Drug Profile

Research programme: urokinase inhibitors - Wilex/4SC

Alternative Names: Urokinase inhibitors research programme - Wilex/4SC

Latest Information Update: 22 Feb 2005

Price : $50

At a glance

  • Originator 4SC; Wilex
  • Class
  • Mechanism of Action Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Jun 2002 Discontinued - Preclinical for Cancer in Germany (unspecified route)
  • 14 Jan 2002 Preclinical development for Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top